Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.63 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | FLT1 | P17948 | 4/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.43 |
| ▸ | VCP | P55072 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617024 | 1.00 | DGAT1 (0.63) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL16546763 | 1.00 | DGAT1 (0.63) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL16546760 | 0.89 | DGAT1 (0.64) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL180807 | 0.89 | DGAT1 (0.64) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL14617025 | 0.89 | DGAT1 (0.64) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL180696 | 0.89 | DGAT1 (0.64) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL16549688 | 0.87 | DGAT1 (0.59) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL180832 | 0.87 | DGAT1 (0.59) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL13664066 | 0.87 | DGAT1 (0.59) | DGAT1SIRT7KDRFLT1FLT4 | |
| SCHEMBL27758115 | 0.85 | DGAT1 (0.52) | DGAT1SIRT7KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103086981-A | New compounds | NOVARTIS AG | 2013-05-08 | — | — | CN | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | claimed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3887388-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SIRT7 2995/4885KDR 4520/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | DGAT1 1023/4885SIRT7 2281/4885KDR 3911/4885 |
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | DGAT1 1629/4885SIRT7 1602/4885KDR 4590/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | DGAT1 1144/4885SIRT7 1450/4885KDR 3841/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | DGAT1 1629/4885SIRT7 1602/4885KDR 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.